Our project, “targeted nanoimmunotherapy against CXCR4+ leukaemic stem cells” has been awarded in the first edition of Miquel Ruttlant research grants, granted by Fundació Investigació Salut i Progress (FISP). This project focuses on the development of a new personalized therapeutic strategy based on nanoimmunotherapy for the treatment of acute myeloid leukemia (AML). The innovative approach combines a precision nanomedicine, developed by the group in collaboration with the Nanobiotechnology Group at the Autonomous University of Barcelona (UAB) and patented by the UAB and IR Sant Pau, which enables the selective elimination of CXCR4+ leukemic stem cells. Additionally, this strategy aims to activate the immune system against malignant cells by inducing immunogenic cell death while integrating immune checkpoint inhibitors to further enhance the immune response.
